Navigation Links
Going a step Further: Phase IV and Post-Marketing Observational Studies add Value to new Therapies, life Science Webinar Hosted by Xtalks

Toronto, Canada (PRWEB) April 23, 2013

The intrinsic differences between clinical trials and real-life drug treatment create safety gaps that can undermine the overall benefit for patients and value of marketed drugs.

Post-Approvals Clinical & Epidemiology Studies (PACES), including Post-Marketing Observational Studies (PMOS) and Phase IV studies, are the only sources of information that allows the assessment of real–life effectiveness and safety. These studies are ideal for generating data regarding patient adherence/compliance to treatment and its impact on effectiveness. Practice patterns and adherence to treatment guidelines by physicians can only be assessed with PACES.

In an exciting new webinar, Dr. John Samplis, Chief Scientific Officer at JSS Medical Research Inc., will cover:

  •     The objectives of PMOS and Phase IV studies
  •     Strategies for designing meaningful PMOS and Phase IV studies
  •     Important considerations when conducting PMOS and Phase IV studies, including: Objectives, Study Design, Statistics, Randomization, Non-standardized follow-up, Data Analysis
  •     The advantages and disadvantages of PMOS and Phase IV compared to other post-approval studies design
  •     Examples of PMOS and Phase IV.

A Q&A with the audience will follow the main presentation.

For more information about this event or to register, visit:

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit

Karen Lim (416) 977-6555 ext 227

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. 3SBio Inc. Enters Into Merger Agreement For "Going Private" Transaction
2. Jennifer Aniston's People's Choice Awards Dress Worries Animal Welfare Advocates; Going Green News Site My Cleaning Products Comments It Was a Bad Pick
3. Arnold Schwarzenegger's Climate Change Law Gets Enacted; Going Green News Site Green Bean Cleaning Urges Public to Help It Help Build a Greener Earth
4. Sitting still or going hunting: Which works better?
5. New fuel cell keeps going after the hydrogen runs out
6. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
7. Blocked holes can enhance rather than stop light going through
8. Ceregene Reports Data From Parkinsons Disease Phase 2b Study
9. Phase II Of HDL, Inc. Headquarters Expansion Begins This Week
10. Benitec Selects University of California, San Diego as a Site for Phase I/II Clinical Trial of TT-034 in Patients with Hepatitis C Infections
11. NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
Post Your Comments:
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... HART ), a biotechnology company developing bioengineered organ implants ... McGorry will present at the LD Micro "Main ... 2:30 p.m. PT. The presentation will be webcast live ... Management will also be available at the conference for ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... Global, Inc., a worldwide provider of clinical research services headquartered in ... company has set a new quarterly earnings record in Q3 of ... for Q3 of 2014 to Q3 of 2015.   ... with the establishment of an Asia-Pacific office ... Kingdom and Mexico , with the ...
Breaking Biology Technology:
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
(Date:11/10/2015)... About signature verification Signature ... identify and verify the identity of an individual ... secure and accurate method of authentication and is ... because each individual,s signature is highly unique. Signature ... signature of an individual is compared and matched ...
Breaking Biology News(10 mins):